X4 Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) was the recipient of some unusual options trading on Monday. Stock traders purchased 2,515 put options on the stock. This is an increase of 132% compared to the typical daily volume of 1,084 put options.

X4 Pharmaceuticals Trading Up 2.8 %

Shares of X4 Pharmaceuticals stock opened at $1.12 on Wednesday. The firm has a 50-day simple moving average of $1.15 and a two-hundred day simple moving average of $0.93. The company has a debt-to-equity ratio of 1.07, a quick ratio of 5.34 and a current ratio of 5.34. X4 Pharmaceuticals has a fifty-two week low of $0.57 and a fifty-two week high of $2.58. The company has a market cap of $188.09 million, a P/E ratio of -1.87 and a beta of 0.48.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.05. As a group, equities analysts predict that X4 Pharmaceuticals will post -0.47 earnings per share for the current fiscal year.

Insider Activity at X4 Pharmaceuticals

In other news, CFO Adam S. Mostafa sold 27,721 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $1.01, for a total value of $27,998.21. Following the transaction, the chief financial officer now directly owns 52,500 shares of the company’s stock, valued at $53,025. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 27,721 shares of X4 Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $1.01, for a total transaction of $27,998.21. Following the completion of the sale, the chief financial officer now directly owns 52,500 shares in the company, valued at approximately $53,025. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Paula Ragan sold 49,678 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $0.88, for a total transaction of $43,716.64. Following the completion of the sale, the chief executive officer now owns 765,068 shares in the company, valued at approximately $673,259.84. The disclosure for this sale can be found here. Insiders have sold a total of 185,708 shares of company stock valued at $170,428 in the last ninety days. Company insiders own 1.08% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new stake in X4 Pharmaceuticals during the 3rd quarter worth approximately $37,000. Barclays PLC boosted its stake in shares of X4 Pharmaceuticals by 334.8% in the third quarter. Barclays PLC now owns 382,134 shares of the company’s stock worth $417,000 after acquiring an additional 294,255 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of X4 Pharmaceuticals in the third quarter worth approximately $678,000. Kingdon Capital Management L.L.C. increased its position in shares of X4 Pharmaceuticals by 76.0% during the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,473,683 shares of the company’s stock worth $2,913,000 after purchasing an additional 1,500,000 shares in the last quarter. Finally, Stonepine Capital Management LLC raised its stake in X4 Pharmaceuticals by 14.5% in the 3rd quarter. Stonepine Capital Management LLC now owns 5,273,685 shares of the company’s stock valued at $5,748,000 after purchasing an additional 668,422 shares during the last quarter. Hedge funds and other institutional investors own 72.03% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright boosted their price target on X4 Pharmaceuticals from $3.00 to $5.00 and gave the company a “buy” rating in a report on Tuesday.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.